{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:37:55Z","timestamp":1791499075353,"version":"4.3.4"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Probiotic-based strategies are increasingly being explored for IBS management, with growing interest in strain-specific applications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the clinical efficacy of <jats:italic>Clostridium butyricum<\/jats:italic> CBM588 and <jats:italic>Bifidobacterium longum<\/jats:italic> W11 in IBS patients with diarrhea-predominant (IBS-D) and constipation-predominant (IBS-C) symptoms, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 51 IBS patients were recruited and stratified into two groups: IBS-D patients received <jats:italic>C. butyricum<\/jats:italic> CBM588 (Butirrisan\u00ae), while IBS-C patients received <jats:italic>B. longum<\/jats:italic> W11 (Bowell\u00ae). Symptom severity was assessed using the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) before and after a 3-month intervention. Generalized linear models and regression analyses were used to evaluate treatment effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both probiotic formulations significantly reduced IBS-SSS scores, particularly improving bloating, abdominal pain, and overall quality of life. The impact of treatment was independent of age, though greater improvements in bloating and life interference were observed in older IBS-C patients. A direct correlation between baseline symptom severity and symptom reduction was identified, suggesting higher efficacy in more severe cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study supports the use of <jats:italic>C. butyricum<\/jats:italic> CBM588 and <jats:italic>B. longum<\/jats:italic> W11 as effective probiotic interventions for IBS-D and IBS-C, respectively. Their strain-specific benefits highlight the potential of targeted probiotic strategies in IBS management. Future studies with larger sample sizes and longer follow-up periods are recommended to confirm and expand these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1604319","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:08:43Z","timestamp":1747735723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11"],"prefix":"10.3389","volume":"12","author":[{"given":"Alexander","family":"Bertuccioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Sisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Lazzerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Palazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano Bruno","family":"Zonzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Ragazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e77053","DOI":"10.7759\/cureus.77053","article-title":"The efficacy of the low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet in irritable bowel syndrome: a systematic review and Meta-analysis","volume":"17","author":"Khan","year":"2025","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"683191","DOI":"10.3389\/fnut.2021.683191","article-title":"A low-FODMAP diet improves the global symptoms and bowel habits of adult IBS patients: a systematic review and Meta-analysis","volume":"8","author":"Wang","year":"2021","journal-title":"Front Nutr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/nrdp.2016.14","article-title":"Irritable bowel syndrome","volume":"2","author":"Enck","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jpsychores.2013.03.004","article-title":"Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model","volume":"74","author":"Van Tilburg","year":"2013","journal-title":"J Psychosom Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.7150\/ijbs.25001","article-title":"Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies","volume":"14","author":"Zhang","year":"2018","journal-title":"Int J Biol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/0019-5545.105520","article-title":"Prevalence of depression and anxiety in irritable bowel syndrome: a clinic based study from India","volume":"55","author":"Kabra","year":"2013","journal-title":"Indian J Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/medicina61010109","article-title":"Impact of microbiota on irritable bowel syndrome pathogenesis and management: a narrative review","volume":"61","author":"Almonajjed","year":"2025","journal-title":"Medicina"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e75954","DOI":"10.7759\/cureus.75954","article-title":"Efficacy of probiotics in the Management of Irritable Bowel Syndrome: a systematic review and Meta-analysis","volume":"16","author":"Almabruk","year":"2024","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/microorganisms9122427","article-title":"Nutraceuticals and herbal food supplements for weight loss: is there a prebiotic role in the mechanism of action?","volume":"9","author":"Bertuccioli","year":"2021","journal-title":"Microorganisms"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1517\/14712598.2013.758711","article-title":"Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and\/or tonsillitis caused by Streptococcus pyogenes in adults","volume":"13","author":"Di Pierro","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41564-020-0721-1","article-title":"Moving from probiotics to precision probiotics","volume":"5","author":"Veiga","year":"2020","journal-title":"Nat Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12602-018-9412-0","article-title":"Correction to: effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth","volume":"11","author":"Leventogiannis","year":"2019","journal-title":"Probiotics Antimicrob Proteins"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/nu12020363","article-title":"Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial","volume":"12","author":"Martoni","year":"2020","journal-title":"Nutrients"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"12538","DOI":"10.3390\/ijms232012538","article-title":"Gut microbiota, metabolic disorders and breast Cancer: could Berberine turn out to be a transversal nutraceutical tool? A narrative analysis","volume":"23","author":"Cazzaniga","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0163743","DOI":"10.1371\/journal.pone.0163743","article-title":"Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a Meta-analysis of randomized controlled trials","volume":"11","author":"L\u00fc","year":"2016","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.3748\/wjg.v25.i33.4999","article-title":"Efficacy of Lactobacillus rhamnosus GG in treatment of acute pediatric diarrhea: a systematic review with meta-analysis","volume":"25","author":"Li","year":"2019","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/apt.12403","article-title":"Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children - updated analysis of randomised controlled trials","volume":"38","author":"Szajewska","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.clnu.2023.08.015","article-title":"Efficacy and safety of probiotics and synbiotics for functional constipation in children: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.3748\/wjg.v29.i35.5178","article-title":"Correction to \u201crole of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: current perspectives\u201d","volume":"29","author":"Roy","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1038\/s41467-022-31171-0","article-title":"Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat Commun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12602-025-10522-5","article-title":"Selection, comparative genomics, and potential probiotic features of Escherichia coli 5C, a pks-negative strain isolated from healthy infant donor feces","volume":"16","author":"Di Pierro","year":"2025","journal-title":"Probiotics Antimicrob Proteins"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"nuae217","DOI":"10.1093\/nutrit\/nuae217","article-title":"Effects of probiotics and diet Management in Patients with Irritable Bowel Syndrome: a systematic review and network Meta-analysis","volume":"25","author":"Lei","year":"2025","journal-title":"Nutr Rev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.mayocp.2018.04.032","article-title":"Management options for irritable bowel syndrome","volume":"93","author":"Camilleri","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1756284819897531","DOI":"10.1177\/1756284819897531","article-title":"Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review","volume":"13","author":"Chey","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut microbiota in patients with irritable bowel syndrome\u2014a systematic review","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology"},{"key":"ref26","first-page":"419","article-title":"Diagnosis and management of IBS in adults","volume":"86","author":"Wilkins","year":"2012","journal-title":"Am Fam Physician"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV\u2014functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref28","first-page":"568","volume-title":"Human intestinal microflora in health and disease","author":"Hentges","year":"1983"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1442-200X.2003.01671.x","article-title":"Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI","volume":"45","author":"Seki","year":"2003","journal-title":"Pediatr Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/abbs\/gmx138","article-title":"Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6","volume":"50","author":"Zhao","year":"2018","journal-title":"Acta Biochim Biophys Sin"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/s41598-018-21241-z","article-title":"The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial","volume":"8","author":"Sun","year":"2018","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1907272","article-title":"Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease","volume":"13","author":"Stoeva","year":"2021","journal-title":"Gut Microbes"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/kjm2.12154","article-title":"Targeting the gut microbiota for the treatment of irritable bowel syndrome","volume":"36","author":"Herndon","year":"2020","journal-title":"Kaohsiung J Med Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/nu15173856","article-title":"Outcome-specific efficacy of different probiotic strains and mixtures in irritable bowel syndrome: a systematic review and network Meta-analysis","volume":"15","author":"Xie","year":"2023","journal-title":"Nutrients"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"587725","DOI":"10.3389\/fmicb.2020.587725","article-title":"Clostridium butyricum MIYAIRI 588-induced Protectin D1 has an anti-inflammatory effect on antibiotic-induced intestinal disorder","volume":"11","author":"Ariyoshi","year":"2020","journal-title":"Front Microbiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e01659-16","DOI":"10.1128\/genomeA.01659-16","article-title":"Complete genome sequence of Bifidobacterium longum W11 (LMG P-21586), used as a probiotic strain","volume":"5","author":"Inturri","year":"2017","journal-title":"Genome Announc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00284-008-9135-7","article-title":"Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains","volume":"56","author":"Izquierdo","year":"2008","journal-title":"Curr Microbiol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.4236\/fns.2014.518192","article-title":"Scanning electron microscopy observation of adhesion properties of bifidobacterium longum W11 and chromatographic analysis of its exopolysaccaride","volume":"5","author":"Inturri","year":"2014","journal-title":"Food Nutr Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1590-8658(06)80227-6","article-title":"Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study","volume":"52","author":"Colecchia","year":"2006","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/B978-0-12-800100-4.00003-9","article-title":"The role of short-chain fatty acids in health and disease","volume":"121","author":"Tan","year":"2014","journal-title":"Adv Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","article-title":"From dietary Fiber to host physiology: short-chain fatty acids as key bacterial metabolites","volume":"165","author":"Koh","year":"2016","journal-title":"Cell"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/microorganisms12081626","article-title":"The anti-constipation effect of Bifidobacterium Longum W11 is likely due to a key genetic factor governing Arabinan utilization","volume":"12","author":"Di Pierro","year":"2024","journal-title":"Microorganisms"},{"key":"ref43","first-page":"111","article-title":"Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms","volume":"78","author":"Dughera","year":"2007","journal-title":"Acta Biomed"},{"key":"ref44","first-page":"157","article-title":"Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir FOS (Bifidobacterium longum W11 + FOS Actilight)","volume":"77","author":"Amenta","year":"2006","journal-title":"Acta Biomed"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.23736\/S1121-421X.19.02622-9","article-title":"Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin","volume":"65","author":"Di Pierro","year":"2020","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4324\/9780203771587","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"2013"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.3748\/wjg.v29.i26.4120","article-title":"Irritable bowel syndrome: epidemiology, overlap disorders, pathophysiology and treatment","volume":"29","author":"Huang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3390\/microorganisms11102369","article-title":"Gut Dysbiosis in irritable bowel syndrome: a narrative review on correlation with disease subtypes and novel therapeutic implications","volume":"11","author":"Napolitano","year":"2023","journal-title":"Microorganisms"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3748\/wjg.v28.i12.1204","article-title":"Antibiotics, gut microbiota, and irritable bowel syndrome: what are the relations?","volume":"28","author":"Mamieva","year":"","journal-title":"World J Gastroenterol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40265-023-01871-y","article-title":"Antibiotics and probiotics for irritable bowel syndrome","volume":"83","author":"Goodoory","year":"2023","journal-title":"Drugs"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2360233","DOI":"10.1080\/19490976.2024.2360233","article-title":"The gut microbiome in disorders of gut\u2013brain interaction","volume":"16","author":"Kraimi","year":"2024","journal-title":"Gut Microbes"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.dld.2024.05.004","article-title":"Microbiota modulation in disorders of gut-brain interaction","volume":"56","author":"Marasco","year":"2024","journal-title":"Dig Liver Dis"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3389\/fpsyt.2020.00664","article-title":"Small intestinal bacterial overgrowth and irritable bowel syndrome \u2013 an update","volume":"11","author":"Takakura","year":"2020","journal-title":"Front Psych"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jgh.16159","article-title":"Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome","volume":"38","author":"Deng","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/gidisord4010004","article-title":"Measurement of pain and related symptoms in irritable bowel syndrome: the use of validated pain measurement tools","volume":"4","author":"Farrukh","year":"2022","journal-title":"Gastrointest Disord"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1604319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:08:47Z","timestamp":1747735727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1604319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":56,"alternative-id":["10.3389\/fmed.2025.1604319"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1604319","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1604319"}}